Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd (Edinburgh, Scotland, UK; CEO: Stephen Myatt; “Macomics”), a leader in macrophage drug discovery, to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Under the terms of the agreement, Macomics will discover antibody candidates against a novel macrophage target identified and validated using its ENIGMAC™ macrophage drug discovery platform. Ono will have an exclusive option to license global rights to the candidates for further development and commercialization. Ono will pay to Macomics an up-front payment, R&D funding, and milestone payments based on development and commercialization progress, as well as tiered royalties based on global net sales.
“Targeting macrophages in immuno-oncology is emerging as an exciting area with significant opportunity to deliver novel therapeutics to improve cancer outcomes and to change the lives of patients with cancer,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. “Macomics has demonstrated the power of its macrophage platform and drug discovery approach and we are delighted to partner with Macomics on taking this novel target discovery program forwards.”
“This global collaboration with Ono is testament to our strong program portfolio, and the unique enablement offered by our ENIGMAC discovery platform, and our world class R&D team,” said Stephen Myatt, CEO of Macomics. “Ono is a leader in immuno-oncology and we are delighted to have a partner in Ono who brings the complementary skills necessary to succeed in this therapeutic area.”
ENIGMAC™ macrophage drug discovery platform integrates large volume human data sets, custom cell models, and proprietary human macrophage genome editing capability to enable identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Macomics Ltd is an immuno-oncology company with world-leading expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its ENIGMAC™ macrophage drug discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
The company was co-founded in 2020 by Prof. Jeffrey Pollard and Dr. Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology. It has R&D and office facilities in Edinburgh and Cambridge, UK and is backed by Epidarex Capital, Scottish Enterprise, LifeLink Ventures and Caribou Property Limited. For more information please visit www.macomics.com and follow us on LinkedIn and https://twitter.com/MacomicsL .